Market Currents
Celgene (CELG +1.4% to $86.92) is the subject of lots of analyst buzz after the company gave a...
-
Tuesday, January 8, 8:25 AM ETCelgene (CELG +1.4% to $86.92) is the subject of lots of analyst buzz after the company gave a positive forecast yesterday. Jefferies raises its price target to $104 from $94 while Stifel Nicolaus ups its goal to $98 from $89, with both firms maintaining Buy ratings. RBC upgrades Celgene to Outperform from Sector Perform and ups its target to $100 from $90, while Piper Jaffray upgrades the biotech to Overweight from Neutral.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
